This White Paper explores the clinical, operational, and financial rationale for adopting FDA-approved generic contrast agents for MRI and CT imaging. These generics meet the same safety and efficacy standards as brand-name products while offering a cost-effective, reliable solution to rising expenses and supply challenges.

Key points:

• Cost savings: Reduces imaging-related expenses.
• Supply stability: Diversifies product access.
• Therapeutic equivalence: Same FDA safety and efficacy standards.
• Clinical validation: Evaluation and ongoing monitoring of quality and safety can help confirm diagnostic equivalence and maintain clinician confidence.
• Collaborative approach: Cross-department coordination supports success.
• Phased rollout: Helps ensure smooth implementation.
• Proven model: UCSD’s transition to Fresenius Kabi generics shows enhanced supply chain stability while maintaining quality patient care.